News

European Vaccine Initiative reports positive clinical trial results for two malaria vaccines and calls for further increase in investments into malaria research and development

TRANSVAC is an infrastructure project that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges.  This short movie explains you what the whole initiative is about.

 

 

Findings from a workshop organised within the VAC2VAC project (Vaccine batch to vaccine batch comparison by consistency testing) on the improved design of multi-centre validation studies and the use the data generated for product-specific validation purposes have now been published (Halder et al, 2018). The recommendations also address aspects of validation within the consistency approach context

European Vaccine Initiative (EVI) begins its third decade developing vaccines for diseases against poverty. Fundraising management and reporting are crucial aspects for EVI’s strategic planning and stakeholders’ engagement.

Thanks to SAP, EVI’s financial reporting is now streamlined and more efficient. For more information, please click here

The first annual meeting of the EU-funded project ZIKAVAX took place on 7 December 2017 at CEA, Fontenay-aux-Roses, France.

EVI has an exciting new Project Manager position. Deadline for applications: 15th January 2018, 17:00 CET. For more information please click here. We look forward to receiving your application.

I4ID, Lyon (France) on December 11-12, 2017

EDCTP funded MVVC2 study published today in Frontiers in Immunology: showing safety and immunogenicity of malaria vectored vaccines given with routine EPI vaccines in Gambian infants and neonates

Fresh funding has been awarded by the GHIT Fund to EVI and its partners from Nagasaki University, German biopharmaceutical firm Mologen AG, Charité - Universitätsmedizin Berlin and the London School of Hygiene and Tropical Medicine (LSHTM) to support the completion of the preclinical development of a novel leishmaniasis vaccine candidate and for preparing the conduct of a future Phase I clinical trial.

The EVI 2016 Annual Report provides an overview of all the activities EVI was involved in during 2016.  We hope it will be an interesting read for you.